BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2129419)

  • 1. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.
    Gillies SD; Wesolowski JS
    Hum Antibodies Hybridomas; 1990; 1(1):47-54. PubMed ID: 2129419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
    Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
    Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen.
    Shaw DR; Khazaeli MB; Sun LK; Ghrayeb J; Daddona PE; McKinney S; LoBuglio AF
    J Immunol; 1987 Jun; 138(12):4534-8. PubMed ID: 3584980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities.
    Robinson RR; Chartier J; Chang CP; Horwitz AH; Better M
    Hum Antibodies Hybridomas; 1991 Apr; 2(2):84-93. PubMed ID: 1873500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system.
    Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL
    Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
    Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
    Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
    Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The construction of a mouse/human chimeric antibody against human breast cancer cells.
    Meulemans E; Vandevyver C; Volckaert G; Raus J
    Year Immunol; 1993; 7():131-6. PubMed ID: 8372502
    [No Abstract]   [Full Text] [Related]  

  • 9. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
    Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
    Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.
    Liu AY; Robinson RR; Murray ED; Ledbetter JA; Hellström I; Hellström KE
    J Immunol; 1987 Nov; 139(10):3521-6. PubMed ID: 3119711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2.
    Sutton VR; Burgess J; Pietersz GA; Li WJ; McKenzie IF; Trapani JA
    Ther Immunol; 1994 Apr; 1(2):83-93. PubMed ID: 7584487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
    Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
    Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
    Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
    Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen and construction of a mouse/human chimeric antibody.
    Shibaguchi H; Arakawa F; Imakiire T; Kuroki M; Kuroki M
    Anticancer Res; 2003; 23(6a):4383-8. PubMed ID: 14666725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
    Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
    Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant mouse/human chimeric anti-colorectal carcinoma antibody cACT19.
    Xiang J; Moyana T; Liu E
    Hum Antibodies Hybridomas; 1994; 5(3-4):105-15. PubMed ID: 7756575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and characterization of a recombinant/chimeric B72.3 (human gamma 1).
    Hutzell P; Kashmiri S; Colcher D; Primus FJ; Hand PH; Roselli M; Finch M; Yarranton G; Bodmer M; Whittle N
    Cancer Res; 1991 Jan; 51(1):181-9. PubMed ID: 1988082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
    Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
    Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing.
    Kaulen H; Seemann G; Bosslet K; Schwaeble W; Dippold W
    Year Immunol; 1993; 7():106-9. PubMed ID: 8372499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.